文献速递免疫规划卫生政策与健康促进

澳大利亚维多利亚州三剂与四剂COVID-19疫苗相对有效性的数据链接研究

The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study.
PubMed 文献 · Vaccine · 2023-12-05

该研究利用澳大利亚维多利亚州常规收集的数据,链接免疫接种、通报、住院和死亡数据,评估2022年6月1日至2023年3月1日Omicron优势流行期间,65岁及以上人群中第三剂和第四剂相对于两剂COVID-19疫苗对住院或死亡的相对有效性(rVE)。结果显示第三剂和第四剂在接种后两周内rVE最高,分别为40%(95%CI:0%至64%)和66%(95%CI:60%至71%),且额外保护随时间减弱。

要点

  • 第三剂和第四剂相对于两剂显著降低65岁及以上人群住院或死亡风险。
  • 接种后两周内rVE最高:第三剂40%(95%CI:0%至64%),第四剂66%(95%CI:60%至71%)。
  • 第三剂和第四剂提供的额外保护随时间推移而减弱。

核心结论

  • 研究结果表明需要额外疫苗剂量和更新的疫苗策略,对公共卫生建议和COVID-19疫苗策略有启示,并需在真实世界环境中进一步研究和监测疫苗有效性。

研究设计与样本

  • 数据链接研究,使用澳大利亚维多利亚州常规收集的数据,链接免疫接种、通报、住院和死亡数据,分析对象为65岁及以上居民,研究期为2022年6月1日至2023年3月1日Omicron优势流行期间。
  • 采用Cox比例风险回归估计相对有效性(rVE),以接种疫苗为时间变化协变量并调整关键混杂因素。

主要发现

  • 在1,070,113名已接种第二剂的65岁及以上人群中,第三剂和第四剂相对于两剂显著降低住院或死亡风险。
  • 接种后两周内rVE最高:第三剂为40%(95%CI:0%至64%),第四剂为66%(95%CI:60%至71%)。
  • 第三剂和第四剂提供的额外保护随时间推移而减弱。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Coronavirus Disease 2019 (COVID-19) pandemic led to extensive vaccination campaigns worldwide, including in Australia. Immunity waning and the emergence of new viral variants pose challenges to the effectiveness of vaccines. Our study aimed to assess the relative effectiveness (rVE) of 3 and 4 compared with 2 doses of COVID-19 vaccine. The study focuses on the Victorian population, a majority of whom had no prior exposure to the virus before vaccination. METHODS: We used routinely collected data for the state of Victoria, Australia, to assess rVE during an Omicron-dominant period, 1 June 2022 to 1 March 2023. Immunisation, notifications, hospitalisations and mortality data for residents aged 65 years and older were linked for analysis. Cox proportional hazard regression was used to estimate the rVE against COVID-19 hospitalisation or death, accounting for key confounders with vaccination as a time-varying covariate. RESULTS: In 1,070,113 people 65 years or older who had received their second dose, a third and fourth dose of a COVID-19 vaccine significantly reduced the hazard of hospitalisation or death compared to two doses. rVE was highest within two weeks from administration at 40 % (95 % CI: 0 % to 64 %) and 66 % (95 % CI: 60 % to 71 %) for a third and fourth dose, respectively. Additional protection conferred by third and fourth doses waned over time from administration. CONCLUSIONS: Our findings underscore the need for additional vaccine doses and updated vaccine strategies. These findings have implications for public health advice and COVID-19 vaccine strategies. Further research and monitoring of vaccine effectiveness in real-world settings are warranted to inform ongoing pandemic response efforts.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Canevari JT, Cheng AC, Wu L, et al. The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study. Vaccine. 2023. PMID: 38057205. doi:10.1016/j.vaccine.2023.11.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。